Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$28.83+0.30 (+1.05%)
Close on Nov 13, 2026Market cap $2.26BP/E –Yield –
Celldex Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Celldex Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$330.73M. For fiscal 2025 it was -$283.99M. The highest annual figure on record is -$3.74M in fiscal 2010.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$283.99M | – |
| FY2024 | Dec 31, 2024 | -$191.90M | – |
| FY2023 | Dec 31, 2023 | -$151.53M | – |
| FY2022 | Dec 31, 2022 | -$112.34M | – |
| FY2021 | Dec 31, 2021 | -$68.18M | – |
| FY2020 | Dec 31, 2020 | -$59.43M | – |
| FY2019 | Dec 31, 2019 | -$50.17M | – |
| FY2018 | Dec 31, 2018 | -$152.86M | – |
| FY2017 | Dec 31, 2017 | -$117.11M | – |
| FY2016 | Dec 31, 2016 | -$129.82M | – |
| FY2015 | Dec 31, 2015 | -$126.54M | – |
| FY2014 | Dec 31, 2014 | -$120.04M | – |
| FY2013 | Dec 31, 2013 | -$79.51M | – |
| FY2012 | Dec 31, 2012 | -$56.03M | – |
| FY2011 | Dec 31, 2011 | -$41.15M | – |
| FY2010 | Dec 31, 2010 | -$3.74M | – |
| FY2009 | Dec 31, 2009 | -$34.27M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$81.09M | – |
| Q2 FY2026 | Jun 30, 2026 | -$79.72M | – |
| Q1 FY2026 | Mar 31, 2026 | -$83.58M | – |
| Q4 FY2025 | Dec 31, 2025 | -$86.34M | – |
| Q3 FY2025 | Sep 30, 2025 | -$72.79M | – |
| Q2 FY2025 | Jun 30, 2025 | -$62.98M | – |
| Q1 FY2025 | Mar 31, 2025 | -$61.87M | – |
| Q4 FY2024 | Dec 31, 2024 | -$55.21M | – |
| Q3 FY2024 | Sep 30, 2024 | -$51.34M | – |
| Q2 FY2024 | Jun 30, 2024 | -$45.52M | – |
| Q1 FY2024 | Mar 31, 2024 | -$39.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$46.87M | – |
| Q3 FY2023 | Sep 30, 2023 | -$40.47M | – |
| Q2 FY2023 | Jun 30, 2023 | -$32.45M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.75M | – |
| Q4 FY2022 | Dec 31, 2022 | -$27.21M | – |
| Q3 FY2022 | Sep 30, 2022 | -$27.03M | – |
| Q2 FY2022 | Jun 30, 2022 | -$35.66M | – |
| Q1 FY2022 | Mar 31, 2022 | -$22.45M | – |
| Q4 FY2021 | Dec 31, 2021 | -$19.56M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.07M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.68M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.86M | – |
| Q4 FY2020 | Dec 31, 2020 | -$24.03M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.48M | – |
| Q2 FY2020 | Jun 30, 2020 | -$10.22M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.70M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.84M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.64M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.10M | – |
| Q1 FY2019 | Mar 31, 2019 | -$16.59M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.40M | – |
| Q3 FY2018 | Sep 30, 2018 | -$6.93M | – |
| Q2 FY2018 | Jun 30, 2018 | -$15.88M | – |
| Q1 FY2018 | Mar 31, 2018 | -$118.65M | – |
| Q4 FY2017 | Dec 31, 2017 | -$24.50M | – |
| Q3 FY2017 | Sep 30, 2017 | -$30.94M | – |
| Q2 FY2017 | Jun 30, 2017 | -$27.93M | – |
| Q1 FY2017 | Mar 31, 2017 | -$33.75M | – |
| Q4 FY2016 | Dec 31, 2016 | -$33.89M | – |
See a number that looks wrong?